V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10412812 | 10057094 | null | null | Adjuvant (A) | 2017-11-07 | 2017-11-07 | Binimetinib + Encorafenib | 01 | N | FLUOROURACIL + MITOMYCIN | 100664219 |
| 10413023 | 10057096 | 1.6 | 65.6 | null | 2019-05-07 | 2019-06-02 | Mogamulizumab | 02 | null | CAPECITABINE + NIVOLUMAB + OXALIPLATIN | 100528365 |
| 10413092 | 10057097 | null | null | Palliative (P) | 2018-09-28 | 2018-11-23 | CYCLOPHOSPHAMIDE + RITUXIMAB | 02 | N | CYTARABINE + ETOPOSIDE + LOMUSTINE + MELPHALAN | 100338791 |
| 10413115 | 10057098 | 1.62 | 65.9 | Palliative (P) | 2017-12-06 | 2017-12-06 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | N | FLUOROURACIL + MITOMYCIN | 100287870 |
| 10413687 | 10057102 | null | null | null | 2018-04-25 | 2018-05-08 | Pemetrexed | 02 | null | INTERFERON ALFA | 100195857 |
| 10413781 | 10057104 | 1.65 | 66 | Palliative (P) | 2019-11-13 | 2019-12-04 | Docetaxel + Trastuzumab (Maint) | N | null | BLEOMYCIN | 100236851 |
| 10413791 | 10057105 | null | null | null | 2018-12-01 | 2019-02-17 | BORTEZOMIB + DARATUMUMAB + THALIDOMIDE | null | null | ISATUXIMAB + POMALIDOMIDE | 100921426 |
| 10413859 | 10057107 | null | null | null | 2021-10-17 | 2021-10-17 | null | null | N | DOXORUBICIN + OLARATUMAB | 100424949 |
| 10414044 | 10057108 | null | null | null | 2018-01-04 | 2018-01-04 | CYTARABINE | null | null | CARBOPLATIN + FLUOROURACIL | 101077913 |
| 10414088 | 10057110 | 1.73 | 53.5 | Neo-adjuvant (N) | null | 2019-07-19 | CHLORAMBUCIL + DEXAMETHASONE + DEXAMETHASONE + ETOPOSIDE | 02 | N | DASATINIB | 101747330 |
| 10414433 | 10057112 | 1.71 | 73.5 | null | 2018-04-05 | 2018-04-11 | Trial Unspecified | 02 | null | AVELUMAB + AXITINIB | 100008163 |
| 10414556 | 10057114 | null | null | Palliative (P) | null | 2017-03-27 | Thalidomide 50mg | N | N | FLAIR TRIAL | 100159373 |
| 10414656 | 10057115 | 1.59 | 0 | null | 2019-04-25 | 2019-05-18 | Docetaxel + nintedanib | 02 | null | FCR | 101015032 |
| 10414738 | 10057116 | null | null | null | 2015-01-26 | 2015-01-26 | AML 19 TRIAL | N | null | CISPLATIN + FLUOROURACIL | 100011192 |
| 10415123 | 10057118 | null | null | null | null | 2020-03-01 | LIPOSOMAL DAUNORUBICIN + CYTARABINE (Vyxeos) | 02 | null | NAB-PACLITAXEL | 100217315 |
| 10415124 | 10057119 | null | null | Curative (C) | 2019-11-06 | 2019-11-06 | EOX | 02 | N | LORLATINIB | 101321236 |
| 10415125 | 10057120 | 1.65 | 95.8 | Palliative (P) | 2016-06-28 | 2016-06-28 | Sunitinib | null | N | OLAPARIB | 101037935 |
| 10415591 | 10057121 | null | null | null | 2019-05-21 | 2019-05-23 | Carboplatin + Pembrolizumab + Pemetrexed | 02 | null | LORLATINIB | 101841788 |
| 10415633 | 10057123 | 1.52 | null | Palliative (P) | 2018-01-19 | 2018-01-27 | BRIGATINIB | 02 | N | CAPECITABINE + CARBOPLATIN | 101175266 |
| 10415757 | 10057124 | 1.63 | 0 | 03 | 2016-10-06 | 2016-10-30 | OXALIPLATIN + MDG + PANITUMUMAB | 02 | N | CAPECITABINE + TEMOZOLOMIDE | 100657848 |
| 10415900 | 10057125 | null | null | Palliative (P) | 2020-03-31 | 2020-04-05 | FEC | 02 | N | CHLORAMBUCIL + OFATUMUMAB | 101412971 |
| 10416056 | 10057127 | 1.62 | 61.4 | null | null | 2018-11-24 | THALIDOMIDE | 2 | null | CAPECITABINE + TEMOZOLOMIDE | 101496031 |
| 10416063 | 10057128 | 1.77 | 62.1 | null | 2014-10-25 | 2020-10-17 | null | 02 | null | BINIMETINIB + ENCORAFENIB | 101234752 |
| 10416224 | 10057129 | 1.78 | 76.4 | Palliative (P) | 2020-12-23 | 2021-03-25 | IRINOTECAN + MDG | 02 | N | CYTARABINE HIGH DOSE | 100714704 |
| 10416573 | 10057134 | 1.8 | 82 | Curative (C) | 2018-01-22 | 2018-02-16 | Rucaparib | 02 | N | NOT MATCHED | 101836152 |
| 10416763 | 10057136 | null | null | null | null | 2018-11-19 | R Chlorambucil | 02 | null | CARBOPLATIN + DOCETAXEL | 101078990 |
| 10417036 | 10057139 | 1.8 | 88.9 | Adjuvant (A) | 2015-12-07 | 2015-12-27 | AML 18 TRIAL | 02 | N | NILOTINIB | 101532615 |
| 10417173 | 10057140 | 1.58 | 91.4 | null | 2018-12-11 | 2020-07-18 | Durvalumab | 02 | null | ERIBULIN | 100458555 |
| 10417251 | 10057141 | 1.81 | 98 | Palliative (P) | 2018-10-25 | 2018-11-16 | Sunitinib | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL + TRASTUZUMAB | 101112452 |
| 10417777 | 10057145 | 0 | 97.9 | Curative (C) | 2018-09-11 | 2018-09-11 | Trabectedin | 02 | N | CISPLATIN + DOCETAXEL + FLUOROURACIL | 100083001 |
| 10418156 | 10057146 | null | null | Palliative (P) | 2017-10-30 | 2017-10-30 | BLEOMYCIN | N | N | CARBOPLATIN + FLUOROURACIL | 100447057 |
| 10418182 | 10057147 | 0 | 87.4 | Neo-adjuvant (N) | 2017-12-26 | 2018-07-21 | Durvalumab | 02 | N | CARFILZOMIB | 100395833 |
| 10418201 | 10057148 | 1.7 | 57 | null | 2018-10-23 | 2019-09-17 | Mitomycin Intravesical | Y | null | EXEMESTANE + RIBOCICLIB | 100024914 |
| 10418210 | 10057149 | 0 | 65.6 | null | 2018-11-11 | 2018-11-21 | CISPLATIN + GEMCITABINE + RITUXIMAB | 02 | null | FCR | 101211663 |
| 10418404 | 10057152 | 1.63 | 59 | null | 2020-01-21 | 2020-01-21 | Obinutuzumab | 02 | null | TALIMOGENE LAHERPAREPVEC | 100076242 |
| 10418509 | 10057154 | 0 | 97 | null | 2018-02-17 | 2018-03-20 | PACLITAXEL + TRASTUZUMAB | 02 | null | CYTARABINE | 101204312 |
| 10418578 | 10057156 | null | null | null | 2018-11-23 | 2019-11-23 | FEC | 02 | null | TRASTUZUMAB EMTANSINE | 100713107 |
| 10418689 | 10057157 | 1.6 | 70.2 | Palliative (P) | null | 2019-01-21 | null | 02 | N | APALUTAMIDE | 100930336 |
| 10418791 | 10057158 | 1.54 | 52 | null | 2017-10-22 | 2017-10-26 | Apalutamide | 1 | null | CISPLATIN + ETOPOSIDE | 100005370 |
| 10419025 | 10057161 | 1.65 | 0 | Palliative (P) | 2019-08-15 | 2019-09-13 | ISATUXIMAB + POMALIDOMIDE | null | N | TRASTUZUMAB EMTANSINE | 100296097 |
| 10419090 | 10057162 | 0 | 73 | Curative (C) | 2017-07-29 | 2019-12-13 | Capecitabine + Mitomycin | 02 | N | BLEOMYCIN + CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + METHOTREXATE + VINCRISTINE | 100035807 |
| 10419147 | 10057163 | 1.59 | 79.6 | Neo-adjuvant (N) | 2019-05-17 | 2019-05-17 | Bevacizumab 7.5mg/kg | 2 | N | BORTEZOMIB + MELPHALAN | 100712481 |
| 10419189 | 10057164 | 1.58 | 97.5 | null | 2020-07-07 | 2020-07-19 | BENDAMUSTINE + CYTARABINE + RITUXIMAB | 02 | null | BINIMETINIB + ENCORAFENIB | 101301716 |
| 10419200 | 10057165 | 1.72 | 65 | null | 2018-02-09 | 2020-02-12 | Binimetinib + Encorafenib | 02 | null | IDELALISIB | 100871374 |
| 10419608 | 10057170 | 1.81 | 61.6 | Palliative (P) | 2017-12-28 | 2018-01-17 | R-GDP | 02 | N | CISPLATIN + FLUOROURACIL | 100265850 |
| 10419665 | 10057171 | 1.77 | 88.8 | null | 2017-12-30 | 2018-01-19 | THALIDOMIDE | 02 | null | CHLORAMBUCIL + RITUXIMAB | 100416010 |
| 10419776 | 10057172 | 1.82 | 88.8 | Curative (C) | 2021-03-24 | 2021-07-18 | LENVATINIB | 02 | N | IRINOTECAN | 100659154 |
| 10419908 | 10057174 | 1.71 | 103 | null | null | 2020-10-17 | CARBOPLATIN + DOCETAXEL + Pertuzumab + Trastuzumab | 02 | null | CHLORAMBUCIL + RITUXIMAB | 101392831 |
| 10420372 | 10057178 | null | null | null | 2019-08-12 | 2019-08-25 | Bevacizumab | 02 | null | AXITINIB | 101838865 |
| 10420420 | 10057179 | 1.61 | 69.1 | Palliative (P) | 2019-03-06 | 2019-03-19 | null | 2 | N | CYCLOPHOSPHAMIDE + RITUXIMAB | 101685822 |